BioXcel Presents Phase 3 Study on BXCL501

Bioxcel Therapeutics ( (BTAI) ) has provided an update.

On November 10, 2025, BioXcel Therapeutics announced the presentation of their Phase 3 study on BXCL501 at the Neuroscience Education Institute Conference. The study, conducted in a home setting, demonstrated that BXCL501 is safe and effective for treating agitation in patients with bipolar disorder or schizophrenia. The trial showed that the drug was well-tolerated with no increase in adverse events over repeated doses, and significantly more patients experienced full resolution of agitation symptoms compared to placebo.

The most recent analyst rating on (BTAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.

Spark’s Take on BTAI Stock

According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.

Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.

To see Spark’s full report on BTAI stock, click here.

More about Bioxcel Therapeutics

BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines for neurological and psychiatric disorders. The company is known for its product BXCL501, a sublingual film formulation of dexmedetomidine, which targets agitation associated with conditions like bipolar disorder and schizophrenia.

Average Trading Volume: 4,626,129

Technical Sentiment Signal: Sell

Current Market Cap: $35.95M

Learn more about BTAI stock on TipRanks’ Stock Analysis page.